Q2 2025 Adaptive Biotechnologies Corp Earnings Call Transcript
Key Points
- Adaptive Biotechnologies Corp (ADPT) achieved profitability in its MRD business this quarter, delivering approximately $2 million in positive adjusted EBITDA.
- MRD revenue grew 42% year over year, driven by significant increases in clinical volume.
- The company successfully integrated clonoSEQ into Flatiron's OncoEMR, expanding access in the community.
- Total company sequencing gross margin improved by 14 percentage points year over year to 64%.
- Adaptive Biotechnologies Corp (ADPT) raised its full-year guidance for MRD revenue and lowered its annual cash burn forecast.
- Despite the positive results, the company still reported a net loss of $25.6 million for the quarter.
- The integration of clonoSEQ into EMR systems is still in early stages, with potential challenges in scaling and optimizing these integrations.
- The company's Immune Medicine business reported an adjusted EBITDA loss, although it improved compared to the previous year.
- There is uncertainty regarding the timing and realization of milestone payments, which could affect financial performance.
- The company faces ongoing challenges in expanding its international market presence and leveraging its existing infrastructure for broader diagnostic applications.
Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies second-quarter 2025 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Karina Calzadilla, Vice President, Investor Relations and FP&A. Please go ahead.
Thank you, Shannon. And good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies' second-quarter 2025 earnings conference call. Earlier today, we issued a press release reporting Adaptive's financial results for the second quarter of '25. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investor section of our corporate website.
During the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
